From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two
 | PharMetrics | MarketScan | ||
---|---|---|---|---|
Baseline characteristics | Abatacept n = 91 | Other bDMARDs n = 3934 | Abatacept n = 137 | Other bDMARDs n = 3559 |
Female | 79 (86.8)* | 2820 (71.7)* | 119 (86.9)* | 2607 (73.3)* |
Age, mean (SD) | 13.4 (3.0)* | 11.2 (4.2)* | 12.6 (3.2)* | 11.4 (4.2)* |
Hospitalized infections | 3 (3.3) | 128 (3.3) | 5 (3.7) | 81 (2.3) |
Uveitis | 3 (3.3)* | 434 (11.0)* | 10 (7.3) | 420 (11.8) |
Non-bDMARDs | 43 (47.3) | 2063 (52.4) | 37 (27.0)* | 1801 (50.6)* |
Treatment pattern Switching to non-bDMARD Discontinuing Staying on abatacept or index bDMARD Switching to other bDMARD | 34 (37.4) 6 (6.6) 35 (38.5)* 16 (17.6) | 1727 (43.9) 362 (9.2) 1114 (28.3)* 731 (18.6) | 41 (29.9)* 14 (10.2) 62 (45.3)* 20 (14.6) | 1680 (47.2)* 364 (10.2) 948 (26.6)* 567 (15.9) |